Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 6 |
| List of Tables | 7 | 2 |
| List of Figures | 9 | 2 |
| Introduction | 11 | 1 |
| Bone Metabolism Therapeutics Market to 2018 - Market Overview | 12 | 4 |
| Introduction | 12 | 1 |
| Revenue | 12 | 1 |
| Annual Cost of Treatment | 13 | 1 |
| Treatment Usage Patterns | 14 | 1 |
| Diseased Population | 15 | 1 |
| Treatment-seeking Population | 15 | 1 |
| Diagnosed Population | 15 | 1 |
| Prescription Population | 15 | 1 |
| Bone Metabolism Therapeutics Market to 2018 - Geographical Landscape | 16 | 15 |
| Revenue Analysis by Geography | 16 | 2 |
| The US | 18 | 1 |
| Revenue | 18 | 1 |
| Annual Cost of Treatment | 19 | 1 |
| Treatment Usage Patterns | 20 | 1 |
| Diseased Population | 21 | 1 |
| Treatment-seeking Population | 21 | 1 |
| Diagnosed Population | 21 | 1 |
| Prescription Population | 21 | 1 |
| Top Five Countries of Europe | 22 | 1 |
| Revenue | 22 | 2 |
| Annual Cost of Treatment | 24 | 1 |
| Treatment Usage Patterns | 25 | 1 |
| Diseased Population | 26 | 1 |
| Treatment-seeking Population | 26 | 1 |
| Diagnosed Population | 26 | 1 |
| Prescription Population | 26 | 1 |
| Japan | 27 | 1 |
| Revenue | 27 | 1 |
| Annual Cost of Treatment | 28 | 1 |
| Treatment Usage Patterns | 29 | 1 |
| Diseased Population | 30 | 1 |
| Treatment-seeking Population | 30 | 1 |
| Diagnosed Population | 30 | 1 |
| Prescription Population | 30 | 1 |
| Bone Metabolism Therapeutics Market to 2018 - Therapeutic Landscape | 31 | 39 |
| Osteoporosis Therapeutics Market | 31 | 1 |
| Introduction | 31 | 1 |
| Revenue | 31 | 1 |
| Revenue by Country | 32 | 2 |
| Branded vs. Generic Market Share | 34 | 1 |
| Annual Cost of Treatment | 35 | 1 |
| Treatment Usage Patterns | 36 | 1 |
| Diseased Population | 37 | 1 |
| Treatment-seeking Population | 37 | 1 |
| Diagnosed Population | 37 | 1 |
| Prescription Population | 37 | 1 |
| Treatment Flow Algorithm | 38 | 1 |
| Drivers and Barriers for the Osteoporosis Therapeutics Market | 39 | 1 |
| Drivers for the Osteoporosis Therapeutics Market | 39 | 1 |
| Barriers for the Osteoporosis Therapeutics Market | 40 | 1 |
| Paget s Disease of Bone Therapeutics Market | 40 | 1 |
| Introduction | 40 | 1 |
| Revenue | 40 | 2 |
| Revenue by Country | 42 | 2 |
| Branded vs. Generic Market Share | 44 | 1 |
| Annual Cost of Treatment | 45 | 1 |
| Treatment Usage Patterns | 46 | 1 |
| Diseased Population | 47 | 1 |
| Treatment-seeking Population | 47 | 1 |
| Diagnosed Population | 47 | 1 |
| Prescription Population | 47 | 1 |
| Treatment Flow Algorithm | 48 | 1 |
| Drivers and Barriers for the Paget s Disease of Bone Therapeutics Market | 49 | 1 |
| Drivers for the Paget s Disease of Bone Therapeutics Market | 49 | 1 |
| Barriers for the Paget s Disease of Bone Therapeutics Market | 49 | 1 |
| Hyperparathyroidism Therapeutics Market | 50 | 1 |
| Introduction | 50 | 1 |
| Revenue | 50 | 2 |
| Revenue by Country | 52 | 2 |
| Branded vs. Generic Market Share | 54 | 1 |
| Annual Cost of Treatment | 55 | 1 |
| Treatment Usage Patterns | 56 | 1 |
| Diseased Population | 57 | 1 |
| Treatment-seeking Population | 57 | 1 |
| Diagnosed Population | 57 | 1 |
| Prescription Population | 57 | 1 |
| Treatment Flow Algorithm | 58 | 1 |
| Drivers and Barriers for the Hyperparathyroidism Therapeutics Market | 59 | 1 |
| Drivers for the Hyperparathyroidism Therapeutics Market | 59 | 1 |
| Barriers for the Hyperparathyroidism Therapeutics Market | 60 | 1 |
| Bone Metastases Therapeutics Market | 60 | 1 |
| Introduction | 60 | 1 |
| Revenue | 60 | 2 |
| Revenue by Country | 62 | 2 |
| Branded vs. Generic Market Share | 64 | 1 |
| Annual Cost of Treatment | 65 | 1 |
| Treatment Usage Patterns | 66 | 1 |
| Diseased Population | 67 | 1 |
| Treatment-seeking Population | 67 | 1 |
| Diagnosed Population | 67 | 1 |
| Prescription Population | 67 | 1 |
| Treatment Flow Algorithm | 68 | 1 |
| Drivers and Barriers for the Bone Metastases Therapeutics Market | 68 | 1 |
| Drivers for the Bone Metastases Therapeutics Market | 68 | 1 |
| Barriers for the Bone Metastases Therapeutics Market | 69 | 1 |
| Bone Metabolism Therapeutics Market to 2018 - Pipeline Analysis | 70 | 17 |
| Introduction | 70 | 2 |
| Bone Metabolism Therapeutics Market - Pipeline Assessment by Clinical Phase of Development | 72 | 1 |
| Filed Molecules | 72 | 1 |
| Phase III | 73 | 5 |
| Phase II | 78 | 2 |
| Phase I | 80 | 1 |
| Preclinical Phase | 81 | 1 |
| Discovery Phase | 82 | 1 |
| Profiles of Promising Molecules in the Bone Metabolism Therapeutics Market | 82 | 1 |
| Alpharadin (radium-223 chloride) | 82 | 1 |
| Introduction | 82 | 1 |
| Mechanism of Action | 82 | 1 |
| Clinical Trial Management | 82 | 1 |
| Orazol (Zoledronic acid) | 83 | 1 |
| Introduction | 83 | 1 |
| Mechanism of Action | 83 | 1 |
| Clinical Trial Management | 83 | 1 |
| Xgeva (denosumab) | 83 | 1 |
| Introduction | 83 | 1 |
| Mechanism of Action | 83 | 1 |
| Clinical Trial Management | 83 | 1 |
| Boniva (ibandronate sodium hydrate) | 84 | 1 |
| Introduction | 84 | 1 |
| Mechanism of Action | 84 | 1 |
| Clinical Trial Management | 84 | 1 |
| Odanacatib (odanacatib) | 85 | 1 |
| Introduction | 85 | 1 |
| Mechanism of Action | 85 | 1 |
| Clinical Trial Management | 85 | 1 |
| GTH-42V | 85 | 1 |
| Introduction | 85 | 1 |
| Mechanism of Action | 85 | 1 |
| Clinical Trial Management | 86 | 1 |
| Viviant (bazedoxifene) | 86 | 1 |
| Introduction | 86 | 1 |
| Mechanism of Action | 86 | 1 |
| Clinical Trial Management | 86 | 1 |
| Bone Metabolism Therapeutics Market to 2018 - Competitive Profiling | 87 | 8 |
| Competitive Profiling | 87 | 1 |
| Amgen Inc. | 87 | 1 |
| Company Overview | 87 | 1 |
| Marketed Drugs | 87 | 1 |
| SWOT Analysis | 88 | 1 |
| Abbott Laboratories | 89 | 1 |
| Company Overview | 89 | 1 |
| Marketed Drugs | 89 | 1 |
| SWOT Analysis | 89 | 1 |
| Genzyme Corporation | 90 | 1 |
| Company Overview | 90 | 1 |
| Marketed Drugs | 90 | 1 |
| SWOT Analysis | 90 | 1 |
| Merck &Co., Inc. | 91 | 1 |
| Company Overview | 91 | 1 |
| Marketed Drugs | 91 | 1 |
| SWOT Analysis | 92 | 1 |
| Novartis AG | 93 | 1 |
| Company Overview | 93 | 1 |
| Marketed Drugs | 93 | 1 |
| SWOT Analysis | 94 | 1 |
| Bone Metabolism Therapeutics Market to 2018 - Strategic Consolidations | 95 | 10 |
| Mergers and Acquisitions | 95 | 2 |
| Segmentation by Deal Value | 97 | 2 |
| Segmentation by Geography | 99 | 1 |
| Co-development Deals | 100 | 1 |
| Summary of Co-development Deals | 101 | 1 |
| Takeda Enters into Co-Development Agreement with Covance in 2011 | 101 | 1 |
| Takeda Enters into Co-Development Agreement with Quintiles in 2011 | 101 | 1 |
| Radius Health Enters into Collaboration Agreement with 3M Drug Delivery Systems in 2011 | 101 | 1 |
| Licensing Deals | 102 | 1 |
| Summary of Licensing Deals | 103 | 1 |
| Orchid Chemicals &Pharmaceuticals Enters into Licensing Agreement with Alvogen in 2010 | 103 | 1 |
| Asahi Kasei Pharma Enters into Licensing Agreement with Novartis Pharma in 2010 | 104 | 1 |
| Osteologix Enters into Licensing Agreement with Servier Research in 2010 | 104 | 1 |
| Ono Pharmaceutical Enters into Licensing Agreement with KAI Pharmaceuticals for KAI-4169 in 2011 | 104 | 1 |
| Bone Metabolism Therapeutics Market to 2018 - Appendix | 105 | 8 |
| Market Definitions | 105 | 1 |
| Abbreviations | 105 | 1 |
| Sources | 106 | 1 |
| Research Methodology | 106 | 2 |
| Coverage | 106 | 1 |
| Secondary Research | 107 | 1 |
| Primary Research | 107 | 1 |
| Therapeutic Landscape | 108 | 3 |
| Epidemiology-based Forecasting | 108 | 2 |
| Market Size by Geography | 110 | 1 |
| Geographical Landscape | 111 | 1 |
| Pipeline Analysis | 111 | 1 |
| Competitive Landscape | 111 | 1 |
| Expert Panel Validation | 111 | 1 |
| Contact Us | 111 | 1 |
| Disclaimer | 112 | 1 |